Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(5 sites)
Spain
Clínica Universidad de Navarra, Pamplona, Navarre Hospital Universitario de Cruces, Barakaldo, Vizcaya Hospital de Galdakao, Galdakao, Vizcaya Fundación Jiménez-Díaz, Madrid Hospital Universitario de Araba, Vitoria-Gasteiz, Álava